A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  • STATUS
    Recruiting
  • End date
    Feb 1, 2026
  • participants needed
    2600
  • sponsor
    Eli Lilly and Company
Updated on 25 November 2020
body mass index
tumor necrosis factor
DMARD
tumor necrosis factor alpha
tumour necrosis
baricitinib
antirheumatics

Summary

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

Details
Treatment Baricitinib, TNF Inhibitor
Clinical Study IdentifierNCT03915964
SponsorEli Lilly and Company
Last Modified on25 November 2020

Adding a note
adding personal notes guide

Select a piece of text and start making personal notes.

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

Study

user name

Annotated by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No made yet